🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 40% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Softgel(s) Serving Size
90 Servings
Other Combinations Product Type
40% Evidence Coverage

Supplement Facts — Evidence Check

Vitamin A
60 mcg RAE (7% DV)
Vitamin C
25 mg (28% DV)
10 mcg (50% DV)
✅ Within RDA (0.7× RDA of 0.015 mg) 📚 604 studies (Tier A: 16, B: 251)
RDA 0.015mg This product: 0.01mg UL 0.1mg
4.05 mg (3375% DV)
📊 33.8× RDA — above typical dose 📚 273 studies (Tier A: 9, B: 175)
RDA 0.12mg This product: 4.05mg
DeltaGOLD
5 mg

Other Ingredients

Sunflower Oil Gelatin Glycerin Water Yellow Beeswax Soy Lecithin

Label Claims — Verification

Nutrient
All Other
All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Suggested Use As a dietary supplement, 1 softgel one or two times daily with meals, or as directed by a healthcare practitioner. Taking with a fat-containing meal may further enhance absorption.

⚠️ Warnings & Precautions

Contraindicated with use of anticoagulant drugs.

Contains: Soy, fish.

🧪 Formulation Notes

Full Spectrum Vitamin K Full Spectrum Vitamin K is a comprehensive vitamin K formula containing vitamins K1 and K2, as well as vitamins A and D, and vitamin E as gamma and delta tocotrienols.

Full Spectrum Vitamin K Three Forms of K with A, D, and E

Additional Information

Keep in a cool, dry place, tightly capped.

Product Details

UPC / SKU 7 13947 75390 7
DSLD Entry Date 2024-09-25
Product Type Other Combinations
Form Softgel Capsule
DSLD ID 317592
Data Updated 2026-04-11

Research Evidence

332 Research Sources
59 Avg Quality Score
220 Meta Analysis
56 Systematic Review
30 Rct
16 Clinical Trial
3 Guideline
3 Regulatory Source
1 Narrative Review
1 Other
1 Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014
View all evidence for Vitamin K →

Compare Similar Products

View all Vitamin K products →